心脏再同步治疗加除颤器与不加除颤器的增量获益
CRT-P组全因死亡率高于CRT-D组(21% vs 12%,p=0.003),但死亡模式分析显示CRT-P组以非心脏性死亡为主(71% vs 38%,p=0.002);多数当代CRT-P候选者死亡主要由非心脏原因驱动,权衡室性快速性心律失常死亡风险与全因死亡风险有助于评估ICD的增量价值。
要点
- CRT-P组全因死亡率高于CRT-D组(21% vs 12%,p=0.003)。
- CRT-P组死亡以非心脏性为主(71% vs 38%,p=0.002)。
- 年龄>80岁、NYHA IV级、β受体阻滞剂不耐受及非缺血性心肌病与ICD增量获益小独立相关。
核心结论
- 当代心衰患者如按当前标准选择CRT-P,其死亡主要由非心脏原因驱动,权衡室性快速性心律失常死亡风险与全因死亡风险有助于评估ICD对CRT-P的增量价值。
主要发现
- CRT-P组5例(1%)出现持续性室性心动过速发作,CRT-D组64例(20%)(p<0.001)。
- 远程监测在4例CRT-P患者中检测到持续性室性心动过速,允许择期升级为CRT-D。
- CRT-P组全因死亡率高于CRT-D组(21% vs 12%,p=0.003),校正基线特征后HR 2.5(95%CI 1.36至4.60;p=0.003)。
- 死亡模式分析显示CRT-P组以非心脏性死亡为主(47例(71%)vs 13例(38%),p=0.002)。
- 多因素分析显示年龄>80岁、NYHA IV级、β受体阻滞剂不耐受及非缺血性心肌病与一级预防ICD在CRT基础上增量价值小独立相关。
临床怎么用
- 对拟行CRT-P的心衰患者,应评估非心脏性死亡风险,以判断加用ICD的增量获益。
- 年龄>80岁、NYHA IV级、β受体阻滞剂不耐受或非缺血性心肌病患者,一级预防ICD在CRT基础上的增量价值可能较小。
- 远程监测有助于发现CRT-P患者持续性室性心动过速,从而择期升级为CRT-D。
局限性
- 回顾性单中心设计。
- CRT-P组年龄更大且合并症负担更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the incremental value of implantable cardioverter defibrillators (ICD) in contemporary optimally treated patients with heart failure (HF) undergoing cardiac resynchronisation therapy (CRT). METHODS: Consecutive patients with HF undergoing CRT-pacemaker (CRT-P) or CRT-defibrillator (CRT-D) implantation in a single tertiary care centre between October 2008 and August 2015 were retrospectively evaluated. For patients with a primary prevention indication of the CRT-D, no benefit of the ICD was defined as absence of appropriate therapy (device analysis) or lethal ventricular tachyarrhythmias (mode of death analysis) during follow-up. RESULTS: 687 patients (CRT-P/CRT-D; n=361/326) were followed for 38±22 months. CRT-P recipients were older (75.7±9.1 vs 71.8±9.3 years; p<0.001) and had a higher comorbidity burden. Five patients with CRT-P (1%) experienced episodes of sustained ventricular-tachycardia vs 64 (20%) patients with CRT-D (p<0.001). Remote tele-monitoring detected the episodes of sustained ventricular tachycardia in four patients with CRT-P, allowing for elective upgrade to CRT-D. All-cause mortality was higher in patients with CRT-P versus CRT-D (21% vs 12%, p=0.003), even after adjusting for baseline characteristics (HR 2.5; 95% CI 1.36 to 4.60; p=0.003). However, mode of death analysis revealed a predominant non-cardiac mode of death in CRT-P recipients (n=47 (71%) vs n=13 (38%) in CRT-D, p=0.002). Multivariate analysis revealed that age >80 years, New York Heart Association class IV, intolerance to beta-blockers and underlying non-ischaemic cardiomyopathy were independently associated with little incremental value of a primary prevention ICD on top of CRT. CONCLUSIONS: The majority of patients with contemporary HF as currently selected for CRT-P exhibit mainly non-cardiac-driven mortality. Weighing risk of ventricular-tachyarrhythmic death versus risk of all-cause mortality helps to address the incremental value of an ICD to CRT-P.
引用
- Martens P, Verbrugge FH, Nijst P, et al. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator. Heart. 2017. PMID: 28716973. doi:10.1136/heartjnl-2017-311423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。